List of miRNAs based therapeutics in their clinical trials
| Therapeutics based on miRNAs and names of companies | Therapeutic agent | The system used for delivery | Disease targeted | Stage of clinical trial | Gov identifier of clinical trial |
|---|---|---|---|---|---|
| Miravirsen (Santaris Pharma) | AntimiR-122 | Antisense inhibitor with LNA modification | Chronic hepatitis C | Phase I is completed | NCT00688012, NCT00979927, NCT01646489 |
| RG-101 (Regulus-therapeutics) | AntimiR-122 | AntimiR conjugated with GalNac | Chronic hepatitis C | Phase II is completed | EudraCT numbers 2015-001535-21, 2015-004702-42 |
| RG-125/AZD4076 (Regulus-therapeutics) | AntimiR-103/107 | AntimiR conjugated with GalNac | Patient with type 2 diabetes | Phase I is completed | NCT02612662, NCT02826525 |
| MRG-106 (miRagen-therapeutics) | AntimiR-155 | Antisense inhibitor with LNA modification | Mycosis fungoides and cutaneous T cell lymphoma | Phase I is completed | NCT02580552 |
| MRG-201 (miRagen-therapeutics) | miR-29 mimic | miRNA duplex with cholesterol conjugation | Scleroderma | Phase II is completed | NCT02603224 |
| MesomiR-1 (EnGeneIC) | miR-16 mimic | Delivery vehicle of EnGeneIC | Mesothelioma and NSCLC | Phase I is completed | NCT02369198 |
| MRX34 (miRNA therapeutics) | miR-34 mimic | Lipid nanoparticles | Multiple-solid tumors | Phase I is terminated | NCT01829971 |
EudraCT numbered trials are registered at EU Clinical Trials Register (clinicaltrialsregister.eu). Gov: government; LNA: locked nucleic acid; NSCLC: non-small cell lung cancer; GalNac: N-acetyl-galactosamine